Influenza virus platforms: New hope for vaccines and cancer immunotherapy
.jpg){kind=link}
Influenza virus is now being engineered to carry foreign genes and reduce virulence, serving not only for next-generation influenza vaccines but also as delivery vectors for heterologous antigens against other infections and cancers, supported by its ability to trigger robust mucosal and systemic immune responses.
Registered users, subscribers or members - SIGN IN
To continue reading this article
Membership
Included as a benefit
Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.
Find out more about how to join.
Register
FREE
Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.
Subscribe
3.75 per month / £35 annually
Get unlimited access to The Microbiologist.